张典瑞
1、新型给药系统及其药物动力学研究;2、中药制剂和中药现代化。
个性化签名
- 姓名:张典瑞
- 目前身份:
- 担任导师情况:
- 学位:
-
学术头衔:
博士生导师
- 职称:-
-
学科领域:
药剂学
- 研究兴趣:1、新型给药系统及其药物动力学研究;2、中药制剂和中药现代化。
张典瑞教授
张典瑞,男,药剂学博士,博士后经历,山东大学药学院教授,博士生导师,山东省第六届青年科技奖获得者。国家自然科学基金项目评审专家,担任International Journal of Pharmaceutics、International Journal of Nanosceince and Nanotechnology 、Journal of Controlled Release 、Asian Journal of Pharmaceutical Sciences等国际期刊审稿人。已在Nanotechnology、International Journal of Biological Macromolecules、International Journal of Pharmaceutics、Journal of Nanoparticle Research等国际杂志发表多篇重要学术论文。在药物制剂、天然产物研究与开发、中药现代化等领域开展了卓有成效的研究工作,主持国家自然科学基金课题2项,山东省自然科学基金课题1项、山东省卫生厅课题1项,先后发表论文30余篇,其中10篇被SCI、EI收录,指导研究生10余名。
研究方向:
1、新型给药系统及其药物动力学研究
2、中药制剂和中药现代化
近期主持承担的科研课题:
1. 国家自然科学基金项目—冬凌草甲素纳米结晶释药系统的相关基础研究,课题负责人。
2. 国家自然科学基金项目—固态类脂纳米粒作为抗癌药冬凌草甲素药物载体的基础研究,课题负责人。
3. 山东省自然科学基金—苍耳子毒性机理研究,课题负责人。
科研工作特色简介:
1. 纳米载体给药系统
纳米载体给药系统为当今药剂学热点研究领域,包括的范围很广,目前主要有固态类脂纳米粒给药系统、聚合物纳米粒给药系统、磁性纳米粒给药系统、长循环纳米粒给药系统、温度敏感性纳米粒给药系统、pH敏感性纳米粒给药系统、光敏感性纳米粒给药系统、免疫纳米粒给药系统、白蛋白纳米粒给药系统多种等。本方向主要从事抗癌药和抗感染药物纳米载体给药系统的研究。已成功对冬凌草甲素固态类脂纳米粒给药系统、苦参碱固态类脂纳米粒给药系统、阿奇霉素固态类脂纳米粒给药系统、冬凌草甲素聚合物纳米粒给药系统、苦参碱白蛋白纳米粒给药系统等进行了研究,并取得了初步研究成果,这些载体可引到药物在体内特异性的分布。
2. 纳米结晶释药系统
纳米结晶释药系统为纳米技术在药物制剂中另一项重要应用,在提高难溶性药物的生物用度和有效性方面具有独特的优点,并且具有明显的靶向性。它不同于纳米粒载体给药系统,它是由纯药物粉体加入适宜表面活性剂等物质经分散制成的胶体分散系统。本方向已初步开展对冬凌草甲素纳米结晶释药系统、阿奇霉素纳米结晶释药系统的研究。
除上述主要研究领域外,近年的工作向多方面展开,主要涉及中药复方制剂的研究、中药药物动力学的研究及新药研发工作等。
-
主页访问
1205
-
关注数
0
-
成果阅读
208
-
成果数
4
【期刊论文】Studies on the oridonin-loaded poly (D, L-lactic acid) nanoparticles in vitro and in vivo
张典瑞, Jie Xing b, Dianrui Zhang a, b, ∗, Tianwei Tan a
International Journal of Biological Macromolecules 40(2007)153-158,-0001,():
-1年11月30日
The purpose of this paper was to investigate the possibility of developing a polymeric nanoparticle delivery system for ORI to increase its solubility, blood circulation time and tissue targeting. Oridonin-loaded poly (D, L-lactic acid) nanoparticles (ORI-PLA-NP) were prepared by the further modified spontaneous emulsion solvent diffusion (MSESD) method. Studies were carried out to characterize and evaluate the produced ORI-PLA-NP both in vitro and in vivo. The experimental results showed that the mean size of the nanoparticles were 137.3nm, with 87.2% of the nanoparticles distributed between the range of 107 and 195nm. The entrapment efficiency and actual drug loading of the nanoparticles were 91.88±1.83 and 2.32±0.05%, respectively. It was demonstrated by differential scanning calorimetry (DSC) and X-ray diffractometry (XRD) that ORI existed in the form of amorphous in the nanoparticles. The in vitro release profile of ORI-PLA-NP could be expressed well by the Higuchi equation: Q=8.944t1/2+11.246. The results of pharmacokinetics demonstrated that being encapsulated in PLA nanoparticles was remarkably effective for ORI to prolong its blood circulation time. After the i.v. administration of ORI-PLA-NP, we could observe a stable and high concentration of ORI in liver, lung and spleen, while its distribution in heart and kidney decreased.
Oridonin, Poly (, D,, L-lactide), acid, Nanoparticles
-
57浏览
-
0点赞
-
0收藏
-
0分享
-
137下载
-
0评论
-
引用
【期刊论文】Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions
张典瑞, Lei Gaoa, Dianrui Zhang a, ∗, Minghui Chenb, Cunxian Duana, Wenting Dai a, Lejiao Jia a, Wenfa Zhaoa
International Journal of Pharmaceutics 355(2008)321-327,-0001,():
-1年11月30日
The purpose of the present study was to investigate the effects of particle size on the pharmacokinetics and tissue distribution of oridonin nanosuspensions after intravenous administration. Two oridonin nanosuspensions with markedly different size were prepared by high pressure homogenization method. The particle size of nanosuspension A is 103.3±1.5nm, while B is 897.2±14.2nm. Dissolution studies showed that complete dissolution could be obtained within 10min for nanosuspension A, however, nanosuspension B showed a slower dissolution, only 85.2% dissolved by 2h. The pharmacokinetics and tissue distribution of oridonin nanosuspensions A and B were studied after intravenous administration using New Zealand rabbits and Kunming mice as experimental animals, respectively. An Oridonin control solution was studied parallelly. The results showed that oridonin nanosuspension A exhibited pharmacokinetic and biodistribution properties similar to solution due to its rapid dissolution in blood circulation. Oridonin nanosuspension B, however, showed a high uptake in RES organs, meanwhile exhibited a markedly different pharmacokinetic property compared to nanosuspension A. These differences could be attributed to the different particle size of the two nanosuspensions considering their zeta potential had no significant difference. In conclusion, particle size showed obvious effects on pharmacokinetics and tissue distribution of nanosuspensions.
Oridonin, Nanosuspensions, High pressure homogenization, Pharmacokinetics, Tissue distribution
-
58浏览
-
0点赞
-
0收藏
-
0分享
-
328下载
-
0评论
-
引用
张典瑞, , 任天池, 娄红祥, 张君华
中国药学杂志,2004,39(2):123~126,-0001,():
-1年11月30日
目的以冬凌草甲素为模型药物,以硬脂酸为载体材料制备冬凌草甲素固态类脂纳米粒,并考察其质量和性质。方法用乳化蒸发一低温固化技术制得了冬凌草甲紊固态夹脂纳米粒,并对其形态、粒径、表面电位、包封率、结构和质量、体外释药特性等进行了研究。结果得到的硬脂酸固态类脂纳米粒为类球形实体,担轻分布比较均匀,平均粒径dav=(22.22±15.5)nm;电位-45.07mY;包封率为(44.83±1.504)%;药物体外释放符合Higuchi方程。用DSC和X-射线衍射分析证明纳米粒确已形成。结论冬凌草甲素可以制成硬脂酸纳米粒,各项物理指标稳定。
oridonin, solid lipid nanoparticles, emulsion evaporation-solldification at low temperature, stearie acid, material phase analys-is
-
38浏览
-
0点赞
-
0收藏
-
0分享
-
29下载
-
0评论
-
引用
张典瑞, , 任天池
中国药学杂志,2003,38(11):817~820,-0001,():
-1年11月30日
目的综述了近30年来国内外有关冬凌草甲素的研究进展。方法分析和归纳了有关冬凌草甲素的结构性质、含量测定方法、荆型研究、药理作用厦临床应用的文献报道。结果与讨论冬凌草甲素的研究主要集中在抗肿瘤活性及机制方面。提取分离和含量测定方法的研究也比较多,但对新剂型及药物动力学的研究较少。
冬凌草甲素, 抗肿瘤, 新剂型
-
55浏览
-
0点赞
-
0收藏
-
0分享
-
33下载
-
0评论
-
引用